XML 47 R33.htm IDEA: XBRL DOCUMENT v3.20.1

Revenues (Tables)

12 Months Ended

Dec. 31, 2019

Revenues [Abstract]

Schedule of net product revenues by product

The Company’s net product revenues consisted of the following for the years ended December 31:

						2019						2018						2017
Products:
Acetadote						$	3,824,449					$	4,284,111					$	6,576,720
Omeclamox-Pak						837,829						623,297						1,761,868
Kristalose						12,895,120						12,055,625						11,455,805
Vaprisol						936,615						1,763,874						1,576,222
Caldolor						5,222,281						5,001,997						4,178,443
Ethyol						12,774,831						10,545,906						10,835,038
Totect						369,912						850,965						3,992,467
Vibativ						8,691,550						5,075,057						—
Total net product revenues						$	45,552,587					$	40,200,832					$	40,376,563

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration